During an initial reproductive endocrinology consultation, a 27-year-old woman seeks evaluation for an inability to conceive over the past 16 months. She previously experienced regular 28-day menstrual cycles, but they became progressively infrequent and completely ceased 8 months ago. Detailed history reveals that over the past year, the patient transitioned to a strict ketogenic diet and began high-intensity training for an ultramarathon, resulting in an intentional 9-kg weight loss. She notes a recent increase in mild facial acne. Her current body mass index is . Vital signs are within normal limits. Pelvic ultrasonography reveals a normal-appearing uterus and bilaterally enlarged ovaries, each containing 15 to 20 small, subcapsular follicles measuring 4 to 8 mm.
Laboratory studies show the following:
Follicle-stimulating hormone: 1.8 mIU/mL
Luteinizing hormone: 1.1 mIU/mL
Estradiol: 15 pg/mL
Prolactin: 9 ng/mL
Thyroid-stimulating hormone: 1.6 mU/L
Total testosterone: 25 ng/dL
Her partner's semen analysis is within normal limits. The patient strongly desires immediate pregnancy and strictly declines any modifications to her current diet or exercise regimen. Which of the following is the most appropriate pharmacologic intervention to induce ovulation in this patient?
- AAdministration of clomiphene citrate
- Administration of exogenous gonadotropinsCevap
- CAdministration of letrozole
- DAdministration of medroxyprogesterone acetate
- EIn vitro fertilization with donor oocytes
Cevap
Because the patient declines lifestyle modifications (which is normally the first-line treatment for FHA), pharmacologic ovulation induction is necessary to treat her infertility. In a hypogonadotropic, hypoestrogenic state, the hypothalamus is fundamentally inactive. Therefore, medications that work by blocking estrogen negative feedback at the hypothalamus to increase endogenous GnRH (such as the aromatase inhibitor letrozole or the selective estrogen receptor modulator clomiphene) are completely ineffective. To achieve ovulation, the central defect must be bypassed by directly stimulating the ovaries with exogenous gonadotropins (FSH and LH) or by administering pulsatile GnRH.